Your browser doesn't support javascript.
loading
Targeting Skin Barrier Function in Atopic Dermatitis.
van den Bogaard, Ellen H; Elias, Peter M; Goleva, Elena; Berdyshev, Evgeny; Smits, Jos P H; Danby, Simon G; Cork, Michael J; Leung, Donald Y M.
Afiliação
  • van den Bogaard EH; Department of Dermatology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Elias PM; Department of Dermatology, University of California San Francisco and VA Medical Center, San Francisco, Calif.
  • Goleva E; Department of Pediatrics, Division of Pediatric Allergy and Immunology, National Jewish Health, Denver, Colo.
  • Berdyshev E; Department of Pulmonology, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colo.
  • Smits JPH; Department of Dermatology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Danby SG; Department of Infection, Immunity and Cardiovascular Disease, The Medical School at The University of Sheffield, Beech Hill Road, Sheffield, UK.
  • Cork MJ; Department of Infection, Immunity and Cardiovascular Disease, The Medical School at The University of Sheffield, Beech Hill Road, Sheffield, UK.
  • Leung DYM; Department of Pediatrics, Division of Pediatric Allergy and Immunology, National Jewish Health, Denver, Colo. Electronic address: Leungd@njhealth.org.
J Allergy Clin Immunol Pract ; 11(5): 1335-1346, 2023 05.
Article em En | MEDLINE | ID: mdl-36805053
ABSTRACT
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the general population. Skin barrier dysfunction is the central abnormality leading to AD. The cause of skin barrier dysfunction is complex and rooted in genetic mutations, interactions between the immune pathway activation and epithelial cells, altered host defense mechanisms, as well as environmental influences that cause epithelial cell activation and release of alarmins (such as thymic stromal lymphopoietin) that can activate the type 2 immune pathway, including generation of interleukins 4 and 13, which induces defects in the skin barrier and increased allergic inflammation. These inflammatory pathways are further influenced by environmental factors including the microbiome (especially Staphylococcus aureus), air pollution, stress, and other factors. As such, AD is a syndrome involving multiple phenotypes, all of which have in common skin barrier dysfunction as a key contributing factor. Understanding mechanisms leading to skin barrier dysfunction in AD is pointing to the development of new topical and systemic treatments in AD that helps keep skin borders secure and effectively treat the disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2023 Tipo de documento: Article